Enable Accessibility Enable Accessibility

List of Shire Products

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for ADDERALL XR®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for ADVATE®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for ADYNOVATE. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for AGRYLIN®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for ANTITHROMBIN III NF®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only

Innomar Strategies, Inc.
Tel: 1-888-960-8746

To Report Suspected Side Effects
Innomar Strategies, Inc.
Tel: 1 888 960 8746

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for CINRYZE®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for CUVITRU®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for ELAPRASE®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for FEIBA® NF. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for Firazyr. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for FOSRENOL®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for GAMMAGARD LIQUID®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for GAMMAGARD S/D®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for IMMUNINE­® VH. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for Intuniv XR®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for MEZAVANT®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for Obizur®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for REPLAGAL®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only

Innomar Strategies, Inc.
Tel: 1-888-960-8746

To Report Suspected Side Effects
Innomar Strategies, Inc.
Tel: 1 888 960 8746

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for REVESTIVE®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for RIXUBIS®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for TAKHZYRO®Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for VONVENDI®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for VPRIV®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 268 2772
E-mail: medinfoCA@takeda.com

To Report Suspected Side Effects
E-mail: AE.CAN@takeda.com

Shire Canada provides Product Monographs for its products as approved by Health Canada and in accordance with federal regulations. Should you wish to obtain more information on a product, please contact your healthcare professional. The information provided in this section is intended for residents of Canada only.

Takeda Canada Inc. is now the market authorization holder for Vyvanse®. Click here to view the Product Monograph.

Canada Contact Information

Medical Information
Intended for Health Care Professionals Only
Tel: 1 800 363 8883
E-mail: medinfo.canada@novartis.com

To Report Suspected Side Effects
Tel: 1 800 363 8883
E-mail: medinfo.canada@novartis.com

On November 22, 2019, the market authorization holder of XIIDRA was transferred to Novartis.
Please visit Novartis website https://www.novartis.ca/en/our-products for the current Product Monograph and the Patient Medication Information.